K
Katerina Zoi
Researcher at Academy of Athens
Publications - 52
Citations - 5257
Katerina Zoi is an academic researcher from Academy of Athens. The author has contributed to research in topics: Uniparental disomy & Atypical chronic myeloid leukemia. The author has an hindex of 22, co-authored 50 publications receiving 4898 citations. Previous affiliations of Katerina Zoi include Foundation for Biomedical Research & University of Southampton.
Papers
More filters
Establishment of the 1st world health organization international genetic referrence panel for quantitation of BCR-ABL mRNA
E. White,P. Matejtschuk,P. Rigsby,J. Gabert,Yirong Wang,S. Branford,N. Muller,N. Beaufils,Emmanuel Beillard,Dolors Colomer,Dana Dvořáková,H. Ehrencrona,Hyun-Gyung Goh,El H. Housni,D. Jones,Veli Kairisto,S. Kamel-Reid,Dw. Kim,S. Langabeer,E. Ma,RD Press,G. Romeo,L. Wang,Katerina Zoi,Timothy P. Hughes,G. Saglio,A. Hochhaus,J. Goldman,P. Metcalfe,Ncp. Cross +29 more
TL;DR: The development of accredited reference reagents that are directly linked to the BCR-ABL international scale is considered a significant milestone in the standardization of this clinically important test, but because they are a limited resource it is suggested that their availability is restricted to manufacturers of secondary reference materials.
Journal ArticleDOI
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha
Amy V. Jones,Richard T. Silver,Katherine Waghorn,Claire Curtis,Sebastian Kreil,Katerina Zoi,Andreas Hochhaus,David Oscier,Georgia Metzgeroth,Eva Lengfelder,Andreas Reiter,Andrew Chase,Nicholas C.P. Cross +12 more
TL;DR: It is found that patients undergoing imatinib or rIFNalpha therapy remained strongly positive for V617F JAK2, although there was a significant reduction in the median percentage of mutant alleles that correlated with hematologic response.
Journal ArticleDOI
Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.
Issa J Dahabreh,Issa J Dahabreh,Katerina Zoi,Stavroula Giannouli,Christine Zoi,Christine Zoi,Dimitrios Loukopoulos,Michael Voulgarelis +7 more
TL;DR: The JAK2 V617F mutation in patients with ET is associated with an increased risk of adverse cardiovascular outcomes via an increase in the leukocyte count and the mean difference of the white blood cell count betweenJAK2 positive and negative patients.
Journal ArticleDOI
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms
Amy V. Jones,Amy V. Jones,Peter J. Campbell,Peter J. Campbell,Philip A. Beer,Susanne Schnittger,Alessandro M. Vannucchi,Katerina Zoi,Melanie J. Percy,Mary Frances McMullin,Linda M. Scott,William J. Tapper,Richard T. Silver,David Oscier,Claire N. Harrison,Harald Grallert,Aliaksei Kisialiou,Paul Strike,Andrew Chase,Andrew Chase,Anthony R. Green,Nicholas C.P. Cross,Nicholas C.P. Cross +22 more
TL;DR: The excess of 46/1 in JAK2 exon 12 cases is compatible with both the "hypermutability" and "fertile ground" hypotheses, but the excess in MPL-mutated cases argues against the former.
Journal Article
Inactivating mutations of the histone methyltransferase EZH2 in myeloid disorders
Thomas Ernst,A Chase,J. Score,Claire Hidalgo-Curtis,C Bryant,Andrew S. Jones,Katherine Waghorn,Katerina Zoi,Fiona M. Ross,Andreas Reiter,A. Hochhaus,Hans G. Drexler,Andrew S Duncombe,F Cervantes,David Oscier,Jacqueline Boultwood,Francis H. Grand,N. C. P. Cross +17 more
TL;DR: Interestingly, the mutations identified resulted in premature chain termination or direct abrogation of histone methyltransferase activity, suggesting that EZH2 acts as a tumor suppressor for myeloid malignancies.